Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies and remains largely refractory to chemotherapy and immunotherapy. Although KRAS inhibitors show promising initial efficacy, resistance rapidly emerges, and immunotherapy responses are mostly restricted to the rare subset of patients with micr...
Chong Zuo, Li Qiang, Madeline Fitzgibbon et al.· Cancer Research· 0 citations
IL-21-elicited CD4 T cells exert anti-tumor activity in mice, and potentially in humans, which can convert transient responses to KRAS inhibition into durable remissions in pancreatic cancer.
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.